

Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) An Immune Response Modifier-support complex comprising at least one Immune Response Modifier compound covalently attached on the surface of particulate support material comprising at least one metal, wherein the at least one IRM compound is a TLR agonist selected from the group consisting of TLR6, TLR7, TLR8, and combinations thereof, and is selected from the group consisting of imidazoquinoline amines, amide substituted imidazoquinoline amines, sulfonamide substituted imidazoquinoline amines, urea substituted imidazoquinoline amines, aryl ether substituted imidazoquinoline amines, heterocyclic ether substituted imidazoquinoline amines, amido ether substituted imidazoquinoline amines, sulfonamido ether substituted imidazoquinoline amines, urea substituted imidazoquinoline ethers, thioether substituted imidazoquinoline amines, 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amines, tetrahydroimidazoquinoline amines, amide substituted tetrahydroimidazoquinoline amines, sulfonamide substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline amines, aryl ether substituted tetrahydroimidazoquinoline amines, heterocyclic ether substituted tetrahydroimidazoquinoline amines, amido ether substituted tetrahydroimidazoquinoline amines, sulfonamido ether substituted tetrahydroimidazoquinoline amines, urea substituted tetrahydroimidazoquinoline ethers, thioether substituted tetrahydroimidazoquinoline amines, imidazopyridine amines, amide substituted imidazopyridine amines, sulfonamide substituted imidazopyridine amines, urea substituted imidazopyridine amines, aryl ether substituted imidazopyridine amines, heterocyclic ether substituted imidazopyridine amines, amido ether substituted imidazopyridine amines, sulfonamido ether substituted imidazopyridine amines, urea substituted imidazopyridine ethers, thioether substituted imidazopyridine amines, 1,2-bridged imidazoquinoline amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazonaphthyridine amines, thiazolonaphthyridine amines, 1*H*-imidazo dimers fused to pyridine amines, quinoline amines,

tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines; pharmaceutically acceptable salts thereof; and combinations thereof.

2. (Canceled)

3. (Canceled)

4. (Previously Presented) The Immune Response Modifier-support complex of claim ~~3~~1 wherein the IRM compound is covalently attached to least one of the metals of the support material.

5. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the support material is in the form of porous particles.

6. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the metal is coated on the support material.

7. (Previously Presented) The Immune Response Modifier-support complex of claim 6 wherein the support material comprises an organic polymer or an inorganic polymer.

8. (Previously Presented) The Immune Response Modifier-support complex of claim 7 wherein the particulate support material comprises a metal oxide.

9. (Previously Presented) The Immune Response Modifier-support complex of claim 8 wherein the particulate support material comprises a glass or a ceramic.

10. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the support material is in the form of solid metal particles.

11. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the metal forms the core of the particulate support material.

12. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the particulate support material has an average density of 0.1 g/cm^3 to 25 g/cm^3 .

13. (Previously Presented) The Immune Response Modifier-support complex of claim 12 wherein the particulate support material has an average density of 5 g/cm^3 to 20 g/cm^3 .

14. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the particulate support material has an average particle size of 1 nanometer to 250 microns.

15. (Previously Presented) The Immune Response Modifier-support complex of claim 14 wherein the particulate support material has an average particle size of 0.1 micron to 20 microns.

16. (Previously Presented) The Immune Response Modifier-support complex of claim 14 wherein the particulate support material has an average particle size of 0.2 micron to 5 microns.

17 - 25 (Cancelled)

26. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the metal is a transition metal, a metalloid, or a rare earth metal.

27. (Previously Presented) The Immune Response Modifier-support complex of claim 26 wherein the metal is selected from the group consisting of Groups 6-11 of the Periodic Table.

28. (Previously Presented) The Immune Response Modifier-support complex of claim 27 wherein the metal is selected from the group consisting of tungsten, iron, gold, silver, platinum, zirconium, nickel, cobalt, rhodium, titanium, and combinations thereof.

29. (Previously Presented) The Immune Response Modifier-support complex of claim 1 wherein the metal is a zero-valent metal.

30. (Previously Presented) The Immune Response Modifier-support complex of claim 29 wherein the zero valent-metal is in the form of an alloy.

31. (Previously Presented) The Immune Response Modifier-support complex of claim 1 further comprising at least one additional drug.

32. (Previously Presented) The Immune Response Modifier-support complex of claim 31 wherein the additional drug is a vaccine.

33. (Previously Presented) The Immune Response Modifier-support complex of claim 32 wherein the vaccine is a DNA vaccine.

34. (Previously Presented) An Immune Response Modifier-support complex comprising at least one IRM compound covalently attached to particulate support material comprising at least one zero-valent transition metal, wherein the particulate support material has an average density of 5 g/cm^3 to 20 g/cm^3 .

35. (Previously Presented) The Immune Response Modifier-support complex of claim 34 contained in a delivery gun.

36. (Previously Presented) The Immune Response Modifier-support complex of claim 34 wherein the metal is selected from the group consisting of tungsten, iron, gold, silver, platinum, zirconium, nickel, cobalt, rhodium, titanium, and combinations thereof.

37. (Previously Presented) An Immune Response Modifier-support complex comprising at least one IRM compound covalently attached to particulate support material comprising at least

one zero-valent transition metal, wherein the particulate support material has an average particle size of 0.2 micron to 5 microns.

38. (Previously Presented) The Immune Response Modifier-support complex of claim 37 wherein the metal is selected from the group consisting of tungsten, iron, gold, silver, platinum, zirconium, nickel, cobalt, rhodium, titanium, and combinations thereof.

39. (Previously Presented) An Immune Response Modifier-support complex comprising at least one IRM compound covalently attached to particulate support material comprising at least one zero-valent transition metal selected from the group consisting of Groups 6-11 of the Periodic Table.

40. (Previously Presented) The Immune Response Modifier-support complex of claim 39 wherein the metal is selected from the group consisting of tungsten, iron, gold, silver, platinum, zirconium, nickel, cobalt, rhodium, titanium, and combinations thereof.

41. (Previously Presented) The Immune Response Modifier-support complex of claim 40 wherein the wherein the particulate support material has an average particle size of 5 nm to 100 nm.

42. (Previously Presented) An Immune Response Modifier-support complex comprising at least one IRM compound covalently attached to an oligonucleotide, which is attached to particulate support material comprising at least one metal.

43. (Previously Presented) The Immune Response Modifier-support complex of claim 42 wherein the particulate support material has an average particle size of 2 microns to 5 microns.

44 - 60 (Cancelled)